The US Food and Drug Administration (FDA) has granted 510(k) approval to Smiths Medical’s neuraxial medication delivery system, designed to minimise the risk of tubing misconnections that occur during spinal and epidural anaesthesia administration.

The new CorrectInject safety system features safety connectors which deliver spinal and epidural medications to the neuraxial region.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The safety system’s yellow components, which visually signify a neuraxial delivery route, help clinicians to check whether the medication to be delivered is appropriate for the treatment location.

The CorrectInject connectors differ from intravenous Luer connectors or intravenous infusion spikes due to the tapered and threaded ends, according to the company.

Smiths Medical president Srini Seshadri said the company is providing a solution that will help clinicians reduce medication delivery errors during spinal and epidural anaesthesia administration.

“As a global leader of safety medical devices, it is our obligation to develop innovative medical products that not only help protect patients when they are most vulnerable but help to raise clinical standards of care,” Seshadri said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

UK-based National Patient Safety Agency (NPSA), US-based World Health Organisation and Joint Commission on Accreditation of Healthcare Organisation support the use of new initiatives to reduce the risk of medication administration errors as well as suggest product developers and manufacturers to produce connector systems dedicated for neuraxial applications.

In addition to the US launch, CorrectInject has been available in the UK, Ireland, Australia and parts of Asia since 2011.